Summary
Abbott Laboratories (ABT) has filed an 8-K to announce a temporary trading suspension, commonly known as a "blackout period," affecting its employee benefit plans. This suspension is due to significant administrative changes within the Abbott Laboratories Stock Retirement Plan (U.S. Plan) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico). These changes include the transition of recordkeepers, trustees for certain U.S. Plan funds, and custodians for certain P.R. Plan funds. Investors should note that while this impacts plan participants' ability to transact within their retirement accounts, it does not directly affect the company's ongoing business operations or its publicly traded stock in the open market. The blackout period is scheduled to commence on December 24, 2025, and is expected to conclude by the week of January 11, 2026. During this time, participants will be unable to make changes to their contributions, investments, loans, withdrawals, or distributions. The company has formally notified its directors and executive officers of these restrictions as required by Sarbanes-Oxley Act regulations.
Key Highlights
- 1Abbott Laboratories is implementing a temporary trading suspension (blackout period) for its U.S. and Puerto Rico employee stock retirement plans.
- 2The blackout period is necessitated by administrative changes, including recordkeeper, trustee, and custodian transitions.
- 3Plan participants will be restricted from making transactions (investments, loans, withdrawals, etc.) within their Plan accounts during the blackout.
- 4The blackout period is expected to begin on December 24, 2025, and end during the week of January 11, 2026.
- 5Company directors and executive officers are also subject to trading restrictions on Abbott common shares during this period, as mandated by the Sarbanes-Oxley Act.
- 6Information about the exact start and end dates of the blackout period can be obtained by contacting Abbott's Compensation and Benefits department.